Navigation Links
Vivakor Announces New Acquisition Strategy
Date:12/9/2009

CORALVILLE, Iowa, Dec. 9 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced its acquisition strategy for the next 12 months. Executive Chairman, Matt Nicosia detailed the key points of the strategy: "We are currently looking at specific transactions involving companies with technologies that fit neatly into our 'hub and spoke' model, as well as companies which have existing commercialization channels that serve our own commercialization strategies for products developed internally." When asked about the timing of any future acquisitions, Mr. Nicosia responded, "We are looking at opportunities all the time. When one appears which fits within our stated strategy, we'll move forward with all due course." Future announcements of any acquisitions will be made as material events occur.

About Vivakor, Inc.

Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and markets and business strategies. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact:

Vivakor Investor Relations

c/o IME Advisors

(888) 648-8485

SOURCE Vivakor, Inc.


'/>"/>
SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Heska Announces Extension of Credit Agreement With Wells Fargo
2. NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock
3. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
4. Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
5. RecoverCare Announces the Relocation of Corporate Headquarters to Louisville
6. Global Announces Contract To Acquire New Business
7. BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in Chinas National Insurance Catalog
8. ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer
9. Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
10. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
11. CompuCyte Announces the Release of Four-Laser Imaging Cytometers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... to announce the addition of micro-needling services in their Napa Valley office. The ... founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen ... stress out of your party preparation – follow these easy, yet delicious recipes with ... game. , “The key to hosting a successful game-day party is creating a flavorful ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, Dr. ... Cheng, CitiDent offers a complete range of oral health care, including general dentistry, ...
(Date:2/5/2016)... ... February 05, 2016 , ... On ... Rare Diseases, a continuing medical education (CME) event presented by the Association for ... kind—and a first for ACCORD, whose mission is to provide education, tools, and ...
Breaking Medicine News(10 mins):